CD274 and non-small cell lung carcinoma: Sarcoma patients treated with pembrolizumab with low-dose cyclophosphamide had three times greater PFS in the TLS-enriched populations vs. all-comers (113), while NSCLC tumors from patients treated with either the PD-L1 inhibitor atezolizumab or chemotherapy showed B cells associated with extended OS following PD-L1 blockade.